Click here to close now.

SYS-CON MEDIA Authors: Adrian Bridgwater, VictorOps Blog, Roger Strukhoff, Elizabeth White, Peter Silva

News Feed Item

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014" provides data on the Spinal Muscular Atrophy (SMA) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Muscular Atrophy (SMA). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Muscular Atrophy (SMA). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Muscular Atrophy (SMA) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Muscular Atrophy (SMA) 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials 29
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Isis Pharmaceuticals, Inc. 32
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 32
Trophos SA 33
Clinical Trial Overview of Trophos SA 33
Westat, Inc. 34
Clinical Trial Overview of Westat, Inc. 34
Repligen Corporation 35
Clinical Trial Overview of Repligen Corporation 35
PTC Therapeutics, Inc. 36
Clinical Trial Overview of PTC Therapeutics, Inc. 36
Natera, Inc. 37
Clinical Trial Overview of Natera, Inc. 37
Hill-Rom Holdings, Inc. 38
Clinical Trial Overview of Hill-Rom Holdings, Inc. 38
GlaxoSmithKline plc 39
Clinical Trial Overview of GlaxoSmithKline plc 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of Top Institutes / Government 41
University of Utah 41
Clinical Trial Overview of University of Utah 41
National Institute of Neurological Disorders and Stroke 42
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 42
Columbia University 43
Clinical Trial Overview of Columbia University 43
Assistance Publique - Hopitaux de Paris 44
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 44
Stanford University 45
Clinical Trial Overview of Stanford University 45
All India Institute of Medical Sciences 46
Clinical Trial Overview of All India Institute of Medical Sciences 46
Nagoya University 47
Clinical Trial Overview of Nagoya University 47
JASMITT Clinical Trial Office 48
Clinical Trial Overview of JASMITT Clinical Trial Office 48
National Taiwan University Hospital 49
Clinical Trial Overview of National Taiwan University Hospital 49
University Hospital Freiburg 50
Clinical Trial Overview of University Hospital Freiburg 50
Five Key Clinical Profiles 51
Appendix 77
Abbreviations 77
Definitions 77
Research Methodology 78
Secondary Research 78
About GlobalData 79
Contact Us 79
Disclaimer 79
Source 79

List of Tables

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Isis Pharmaceuticals, Inc., 2014* 32
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2014* 33
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Westat, Inc., 2014* 34
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Repligen Corporation, 2014* 35
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by PTC Therapeutics, Inc., 2014* 36
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Natera, Inc., 2014* 37
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hill-Rom Holdings, Inc., 2014* 38
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 39
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 40
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Utah, 2014* 41
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 42
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Columbia University, 2014* 43
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 44
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 45
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 46
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagoya University, 2014* 47
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by JASMITT Clinical Trial Office, 2014* 48
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 49
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Freiburg, 2014* 50

List of Figures

Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Muscular Atrophy (SMA) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Muscular Atrophy (SMA) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Muscular Atrophy (SMA) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Muscular Atrophy (SMA) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Muscular Atrophy (SMA) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Muscular Atrophy (SMA) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 78

To order this report: Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280946/Spinal-Muscular-Atrophy-SMA-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in adop...
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists addressed the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affect t...
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
SYS-CON Events announced today that BMC will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. BMC delivers software solutions that help IT transform digital enterprises for the ultimate competitive business advantage. BMC has worked with thousands of leading companies to create and deliver powerful IT management services. From mainframe to cloud to mobile, BMC pairs high-speed digital innovation with robust...
Even as cloud and managed services grow increasingly central to business strategy and performance, challenges remain. The biggest sticking point for companies seeking to capitalize on the cloud is data security. Keeping data safe is an issue in any computing environment, and it has been a focus since the earliest days of the cloud revolution. Understandably so: a lot can go wrong when you allow valuable information to live outside the firewall. Recent revelations about government snooping, along...
There will be 150 billion connected devices by 2020. New digital businesses have already disrupted value chains across every industry. APIs are at the center of the digital business. You need to understand what assets you have that can be exposed digitally, what their digital value chain is, and how to create an effective business model around that value chain to compete in this economy. No enterprise can be complacent and not engage in the digital economy. Learn how to be the disruptor and not ...
DevOps tends to focus on the relationship between Dev and Ops, putting an emphasis on the ops and application infrastructure. But that’s changing with microservices architectures. In her session at DevOps Summit, Lori MacVittie, Evangelist for F5 Networks, will focus on how microservices are changing the underlying architectures needed to scale, secure and deliver applications based on highly distributed (micro) services and why that means an expansion into “the network” for DevOps.
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.